Program
Istaroxime
Also written as “istaroxime”.
Its studies are mostly in Heart Failure · Shock, Cardiogenic, led by 5 companies.
Drug pageIstaroxime: every studyMany companies study it; this page follows only the 8 they lead. All 9 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Windtree Therapeuticsits history only | 31 open or running | phase 2since Jul 9, 2015 | Jul 9, 2015 | none ahead |
| Debiopharmits history only | 20 open or running | phase 2since Feb 5, 2009 | Feb 5, 2009 | none ahead |
| Lee's Pharmaceutical | 10 open or running | phase 1since Jun 17, 2015 | Jun 17, 2015 | none ahead |
| Seismic Pharmaceuticals Operationsits history only | 11 open or running | phase 3since May 1, 2026 | May 1, 2026 | Dec 2028phase 3 · NCT07583446 |
| sigma-tau i.f.r.its history only | 10 open or running | phase 2since Feb 5, 2008 | Feb 5, 2008 | none ahead |
Also a collaborator on its studies: CVie Therapeutics, Momentum Research and MDS Pharma Services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Lee's Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 17, 2015First study: phase 1 study in HealthyFirst studyNCT02477449 · 32 enrolled · China
TargetBeta
“Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator”ChEMBL 37, by rule
Studies
The one study Lee's Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02477449Healthy · China | 1 | Completed | Oct 2015 | 32 |
How it is read
Names in the registry
- “Istaroxime”, 13 entries
- “istaroxime”, 2 entries
Conditions, from the studies’ own filings
- Heart Failure, 4 studies
- Shock, Cardiogenic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.